(Reuters) – Britain’s GSK said on Monday it had halted enrolment and vaccination in three trials evaluating its vaccine candidate against the respiratory syncytial virus (RSV) in pregnant women, days after pausing the studies following some safety snags.
The world’s biggest vaccine maker by sales reiterated that the halt did not affect another trial of its RSV vaccine candidate for adults aged 60 and over, adding that analysis of the safety data from maternal trials is ongoing.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Anil D’Silva)
